NCT03719170 - Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program | Biotech Hunter

Enrollment

220,306

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

September 15, 2021

Study Completion Date

November 30, 2021

Conditions

Proton Pump Inhibitors

Interventions

BEHAVIORAL

PPI De-prescribing Program

The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.

Trial Locations (4)

19104

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia

48105

VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor

84148

VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City

06516

VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven

All Listed Sponsors

lead

VA Office of Research and Development

FED